Affidea Partners With Skin Analytics to Improve Access to Skin Cancer Assessment Across Europe Using AI Technology
As part of this partnership, Affidea has implemented Skin Analytics' DERM, an AI medical device software for the automated analysis of skin lesions. The initial implementation of DERM began in Romania and Lithuania, with Greece to follow in September. These countries were selected based on market analysis, clinical readiness and innovation focus. The aim is to improve patient access to high quality care by introducing clinically validated AI technology into the gold standard skin care pathway already in place. This enables patients' triage while streamlining workflows. Following this first phase, Affidea plans to roll out the AI solution across additional European markets.
Dr. Charles Niehaus, executive director for Affidea Group, stated: "Integrating cutting-edge digital innovations into clinical practice is essential to delivering the best possible care for our patients. Our partnership with Skin Analytics marks an exciting milestone, enabling us to leverage AI in supporting early detection of skin cancer and to provide even more patients with access to the prevention, diagnosis, and treatment programs we already offer in our dermatology units. This collaboration is not just about introducing new technology — it's about creating scalable, sustainable solutions that empower patients and clinical teams, address rising demand and bring timely, high-quality care across Europe."
Neil Daly, founder and CEO of Skin Analytics, stated: 'We're incredibly proud to be partnering with Affidea as our first European partner. This collaboration represents a major milestone in our mission to transform access to dermatology care using AI. By combining Affidea's clinical excellence and pan-European reach with our proven technology, DERM, we have an opportunity to reimagine how skin cancer is identified and managed across the continent. At scale, this partnership will drive earlier diagnoses, improve access to care and support dermatology teams facing rising demand — ultimately marking history for how skin cancer care is delivered and improving outcomes for patients across Europe.'
Skin cancer remains a significant public health challenge across Europe. According to GLOBOCAN 2022 data, Europe accounts for approximately 10.4 melanoma cases per 100,000 people. Non-melanoma skin cancers were even more prevalent, with over 1.15 million cases in Europe in 2022 [1]. This burden continues to grow — age-standardised incidence rates for melanoma have risen sharply over the past decades, and non-melanoma cases now represent nearly 78% of all skin cancer diagnoses.
Source
[1] Global Cancer Observatory, International Agency for Research on Cancer: https://gco.iarc.who.int/media/globocan/factsheets/cancers/17-non-melanoma-skin-cancer-fact-sheet.pdf, opens new tab
About Affidea Group
Affidea is a leading pan-European provider of specialist healthcare services, including cancer care, community-based polyclinics and advanced diagnostic imaging. Founded in 1991, the company operates over 410 centres across 15 countries, with more than 14 million patient visits every year. Affidea is majority-owned by Groupe Bruxelles Lambert (GBL), a leading investment holding company, focused on long-term value-creation with a stable and supportive family shareholder base. For more information, visit www.affidea.com, opens new tab.
For media inquiries regarding Affidea Group, contact oana.dumitroiu@affidea.com, opens new tab.
About Skin Analytics
Skin Analytics was founded in 2012 by Neil Daly to help more people survive cancer. It began providing teledermatology services in 2015 and since 2020 is now deployed in 27 NHS sites across the UK, having seen more than 180,000 NHS patients and detected more than 15,500 cancers. Post-market surveillance has shown that DERM found 97% of cancers (and accurately identified over 75% of benign lesions) with a negative predictive value (NPV) of 99.6% for all skin cancers. Settings in which DERM has been deployed have been able to reduce the number of face-to-face dermatologist appointments required for the volume of suspected skin cancer referrals by 60 to 95%, and DERM can autonomously discharge up to 40% urgent suspected skin cancer referrals. DERM is the only Class III CE marked AI Dermatology medical device, enabling Skin Analytics to begin actively expanding its lifesaving services to Europe. For more information, visit skin-analytics.com, opens new tab.
For media inquiries regarding Skin Analytics, contact skin@transatlanticent.com, opens new tab.
About DERM
DERM is an AI medical device (AIaMD), operating under a Class III CE mark. DERM is intended for use in the screening, triage and assessment of skin lesions suspicious for skin cancer. DERM will analyse a dermoscopic image of a skin lesion and return a suspected diagnosis and, if applicable, a referral recommendation for the lesion. DERM is indicated for use on dermoscopic images of cutaneous lesions where there is a suspicion of skin cancer in patients aged 18 years or over in any body location except where specific exclusions apply. Deployed across NHS sites in the UK, Skin Analytics pathways have seen more than 180,000 patient cases and supported the identification of over 15,500 cancers. With a negative predictive value rate of 99.9% for ruling out melanomas, the platform has become a proven tool for aiding clinical decision-making while enhancing patient access and efficiency within skin cancer pathways.
Media Contact
Oana Dumitroiuoana.dumitroiu@affidea.com
###
SOURCE: Affidea Group
Copyright 2025 EZ Newswire
See release on EZ Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
40 minutes ago
- Reuters
Palo Alto's forecasts signals AI boost for cybersecurity tools
Aug 18 (Reuters) - Palo Alto Networks (PANW.O), opens new tab forecast fiscal 2026 revenue and profit above Wall Street estimates on Monday, betting on growing demand for its artificial intelligence-powered cybersecurity solutions, sending its shares up nearly 5% in extended trading. The company has been benefiting from an AI-driven upgrade cycle as enterprises accelerate their cloud adoption and modernize security operations amid rising data breach incidents. A wave of high-profile cyberattacks has hit global companies including Microsoft (MSFT.O), opens new tab, UnitedHealth Group (UNH.N), opens new tab, Walt Disney (DIS.N), opens new tab and Oracle (ORCL.N), opens new tab, prompting the need for robust security solutions. Palo Alto's new launches such as cloud security platform 'Cortex Cloud' and security platform to protect AI apps 'Prisma AIRS', together with its planned $25 billion CyberArk acquisition, deepen its cybersecurity offerings. The company also announced that founder and Chief Technology Officer Nir Zuk will be retiring after being with Palo Alto for over 20 years. Long-time product leader Lee Klarich has been named as its CTO and board member. Klarich will also chair the board's security committee in a bid to bolster the company's AI-driven platform strategy. Palo Alto competes with CrowdStrike (CRWD.O), opens new tab, Fortinet (FTNT.O), opens new tab and Zscaler (ZS.O), opens new tab. Its customers include Salesforce (CRM.N), opens new tab, Dell Technologies (DELL.N), opens new tab and NetApp (NTAP.O), opens new tab. The company projected annual revenue between $10.48 billion and $10.53 billion, above analysts' average estimate of $10.43 billion, according to data compiled by LSEG. It expects adjusted profit per share of $3.75 to $3.85, above estimates of $3.67 for the fiscal year. The company's first-quarter revenue forecast of $2.45 billion to $2.47 billion came in above expectations of $2.43 billion. Its adjusted quarterly earnings per share of 88 cents to 90 cents was also above estimates of 85 cents. Palo Alto reported upbeat fourth-quarter results. Its revenue grew 16% to $2.54 billion from a year ago. It reported adjusted EPS of 95 cents for the quarter ended July 31, beating estimates of 88 cents.
Reuters
an hour ago
- Reuters
Exclusive: Arm hires Amazon AI chip director to aid in-house effort
SAN FRANCISCO, Aug 18 (Reuters) - Arm Holdings has hired former (AMZN.O), opens new tab artificial intelligence chip director Rami Sinno to bolster its plans to develop its own complete chips, according to a person familiar with the matter. Sinno was responsible for helping to develop Amazon's homegrown AI chips called Tranium and Inferentia that are designed to help build and run large AI applications. Arm has sought to expand its ambitions from a supplier of crucial chip intellectual property to build its own complete designs. Reuters first reported on the company's plans outlined in sealed exhibits from a December trial, and its effort to hire executives from rivals in February.
The Guardian
an hour ago
- The Guardian
On the Edge review – gripping study of France's overstretched mental health system
Within the corridors of a psychiatric ward in Beaujon hospital in Clichy, Paris, tensions run high. Every day, a steady stream of patients pours in, while resources are stretched pitifully thin. Through jagged handheld cinematography, Nicolas Peduzzi's gripping and passionate documentary reflects the facility's breakneck pace. Amid a flurry of frantic calls and rolling stretchers, a calm presence emerges: here comes Dr Jamal Abdel-Kader, the only staff psychiatrist in the building. The camera trails after Abdel-Kader's hurried steps as he splits his day between various departments, from the emergency rooms to the intensive care units. Despite his colossal workload – a result of crumbling infrastructure and lack of government budget – he devotes his full attention to each individual patient. Some are only in their late teens when they attempt self-harm and even suicide. Others have already spent a lifetime trapped in a cycle of addiction and depression. Although their situations vary, the patients' circumstances all point to structural issues in France's treatment of mental health. Abdel-Kader perceives the private struggles of his patients not simply as personal failings, but as symptoms of an indifferent society, in which people have forgotten how to care for one another. Besides medical intervention, his treatment also includes other forms of therapy, including creative sessions where people gather to study Molière and Shakespeare. Abdel-Kader's conversations with colleagues reveal that the loneliness endured by the patients also extends to the overworked physicians, who are undersupported by the state. These moments of introspection at the hospital, expressed in black-and-white snapshots, lend a human touch to spaces that are still painfully stigmatised in the public eye. In contrast to the outside world driven by productivity and prejudice, here is where care and understanding still exist, against all odds. On the Edge is on True Story from 22 August.
